Overview

Gender

male

Mr. Johnson serves on the boards of directors for a number of life science companies.

He is currently a director for Mirati Therapeutics, Inc. and Adamis Pharmaceuticals Corporation.

Mr. Johnson also served as a director for Ardea Biosciences, Inc., from 2008 until its sale to AstraZeneca PLC in 2012. He was Chief Financial Officer of PURE Bioscience, Inc. from 2011 to 2012, and Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. from 2010 to 2011.

Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President for a wholly owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. He held several positions at MitoKor, Inc. from 1994 to 2004, including Chief Financial Officer and Senior Vice President of Operations.

Prior to 1994, Mr. Johnson held senior financial positions with several early-stage technology companies, and he also practiced as a Certified Public Accountant with Price Waterhouse.

Mr. Johnson received his B.B.A. in accounting from the University of Michigan-Dearborn.